Study S003372

Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT07697846
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 40
Start: 2026-07-18
Primary completion: 2027-01-13
Lead sponsor: Beijing QL Biopharmaceutical Co.,Ltd
Conditions: Overweight, Obesity
Interventions: DRUG:ZT002 injection; DRUG:ZT002 injection matching placebo
Results posted: FALSE

Registered primary outcomes

Change to baseline- and placebo-corrected QTc interval (ΔΔQTc) [Up to Day 141]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.